Talía Malagón
McGill University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Talía Malagón.
Journal of the National Cancer Institute | 2012
Nicolas Van de Velde; Marie-Claude Boily; Mélanie Drolet; Eduardo L. Franco; Marie-Hélène Mayrand; Erich V. Kliewer; François Coutlée; Jean-François Laprise; Talía Malagón; Marc Brisson
BACKGROUND Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now licensed in several countries. Furthermore, clinical trials examining the efficacy of a nonavalent vaccine are underway. We aimed to compare the potential population-level effectiveness of the bivalent, quadrivalent, and candidate nonavalent HPV vaccines. METHODS We developed an individual-based, transmission-dynamic model of HPV infection and disease in a population stratified by age, gender, sexual activity, and screening behavior. The model was calibrated to highly stratified sexual behavior, HPV epidemiology, and cervical screening data from Canada. RESULTS Under base case assumptions, vaccinating 12-year-old girls (70% coverage) with the bivalent (quadrivalent) vaccine is predicted to reduce the cumulative incidence of anogenital warts (AGWs) by 0.0% (72.1%), diagnosed cervical intraepithelial neoplasia lesions 2 and 3 (CIN2 and -3) by 51.0% (46.1%), and cervical squamous cell carcinoma (SCC) by 31.9% (30.5%), over 70 years. Changing from a bivalent (quadrivalent) to a nonavalent vaccine is predicted to reduce the cumulative number of AGW episodes by an additional 66.7% (0.0%), CIN2 and -3 episodes by an additional 9.3% (12.5%), and SCC cases by an additional 4.8% (6.6%) over 70 years. Differences in predicted population-level effectiveness between the vaccines were most sensitive to duration of protection and the time horizon of analysis. The vaccines produced similar effectiveness at preventing noncervical HPV-related cancers. CONCLUSIONS The bivalent vaccine is expected to be slightly more effective at preventing CIN2 and -3 and SCC in the longer term, whereas the quadrivalent vaccine is expected to substantially reduce AGW cases shortly after the start of vaccination programs. Switching to a nonavalent vaccine has the potential to further reduce precancerous lesions and cervical cancer.
Journal of the National Cancer Institute | 2016
Marc Brisson; Jean-François Laprise; Harrell W. Chesson; Mélanie Drolet; Talía Malagón; Marie-Claude Boily; Lauri E. Markowitz
BACKGROUND Randomized clinical trials have shown the 9-valent human papillomavirus (HPV) vaccine to be highly effective against types 31/33/45/52/58 compared with the 4-valent. Evidence on the added health and economic benefit of the 9-valent is required for policy decisions. We compare population-level effectiveness and cost-effectiveness of 9- and 4-valent HPV vaccination in the United States. METHODS We used a multitype individual-based transmission-dynamic model of HPV infection and disease (anogenital warts and cervical, anogenital, and oropharyngeal cancers), 3% discount rate, and societal perspective. The model was calibrated to sexual behavior and epidemiologic data from the United States. In our base-case, we assumed 95% vaccine-type efficacy, lifelong protection, and a cost/dose of
Vaccine | 2014
Jean-François Laprise; Mélanie Drolet; Marie-Claude Boily; Mark Jit; Chantal Sauvageau; Eduardo L. Franco; Philippe Lemieux-Mellouki; Talía Malagón; Marc Brisson
145 and
Vaccine | 2013
Talía Malagón; Véronique Joumier; Marie-Claude Boily; Nicolas Van de Velde; Mélanie Drolet; Marc Brisson
158 for the 4- and 9-valent vaccine, respectively. Predictions are presented using the mean (80% uncertainty interval [UI] = 10(th)-90(th) percentiles) of simulations. RESULTS Under base-case assumptions, the 4-valent gender-neutral vaccination program is estimated to cost
Cancer Epidemiology, Biomarkers & Prevention | 2015
Talía Malagón; Mélanie Drolet; Marie-Claude Boily; Jean-François Laprise; Marc Brisson
5500 (80% UI = 2400-9400) and
The Journal of Infectious Diseases | 2017
Talía Malagón; Ann N. Burchell; Mariam El-Zein; Julie Guénoun; Pierre-Paul Tellier; François Coutlée; Eduardo L. Franco; Gail Kelsall; Suzanne Dumais; Melanie Drew; Natalia Morykon; Amela Rocamora; Nathalie Slavtcheva; Allita Rodrigues; Vicky D’Anjou-Pomerleau; Jennifer Selinger; Elizabeth Montpetit-Dubrule; Jessica Sammut; Emilie Lapointe; Johanna Bleecker; Shady Rahayel; Hélène Voyer; Véronique Legault; Emilie Comète
7300 (80% UI = 4300-11 000)/quality-adjusted life-year (QALY) gained with and without cross-protection, respectively. Switching to a 9-valent gender-neutral program is estimated to be cost-saving irrespective of cross-protection assumptions. Finally, the incremental cost/QALY gained of switching to a 9-valent gender-neutral program (vs 9-valent girls/4-valent boys) is estimated to be
Archive | 2018
Talía Malagón; Eduardo L. Franco
140 200 (80% UI = 4200->1 million) and
Expert Review of Vaccines | 2018
Talía Malagón; Cassandra Laurie; Eduardo L. Franco
31 100 (80% UI = 2100->1 million) with and without cross-protection, respectively. Results are robust to assumptions about HPV natural history, screening methods, duration of protection, and healthcare costs. CONCLUSIONS Switching to a 9-valent gender-neutral HPV vaccination program is likely to be cost-saving if the additional cost/dose of the 9-valent is less than
Sexually Transmitted Diseases | 2017
Talía Malagón; Ann N. Burchell; Mariam El-Zein; Julie Guénoun; Pierre-Paul Tellier; François Coutlée; Eduardo L. Franco
13. Giving females the 9-valent vaccine provides the majority of benefits of a gender-neutral strategy.
Lancet Infectious Diseases | 2012
Talía Malagón; Mélanie Drolet; Marie-Claude Boily; Eduardo L. Franco; Mark Jit; Jacques Brisson; Marc Brisson
BACKGROUND Recent evidence suggests that two doses of HPV vaccines may be as protective as three doses in the short-term. We estimated the incremental cost-effectiveness of two- and three-dose schedules of girls-only and girls & boys HPV vaccination programmes in Canada. METHODS We used HPV-ADVISE, an individual-based transmission-dynamic model of multi-type HPV infection and diseases (anogenital warts, and cancers of the cervix, vulva, vagina, anus, penis and oropharynx). We conducted the analysis from the health payer perspective, with a 70-year time horizon and 3% discount rate, and performed extensive sensitivity analyses, including duration of vaccine protection and vaccine cost. FINDINGS Assuming 80% coverage and a vaccine cost per dose of